Research programme: claudin antagonists - Adherex Technologies

Drug Profile

Research programme: claudin antagonists - Adherex Technologies

Latest Information Update: 23 Feb 2011

Price : $50

At a glance

  • Originator Adherex Technologies
  • Class
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Aug 2006 No development reported - Preclinical for Cancer in Canada (unspecified route)
  • 18 May 2004 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top